- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07627984
Cerebral Embolic Protection Device During TAVR
2. juni 2026 oppdatert av: Shanghai Shenqi Medical Technology Co., Ltd
A Prospective, Multicenter, Randomized Controlled Clinical Trial to Evaluate the Safety and Efficacy of a Cerebral Embolic Protection Device for Capturing and Removing Thrombus/Tissue Debris During Transcatheter Aortic Valve Replacement
To evaluate the safety and effectiveness of the Cerebral Protection System (model CEP016F, Shanghai Shenqi Medical Technology Co., Ltd.) for capturing and removing thrombotic and tissue debris during transcatheter aortic valve replacement (TAVR).
Studieoversikt
Status
Fullført
Intervensjon / Behandling
Detaljert beskrivelse
This study is a prospective, multicenter, randomized controlled clinical trial designed to evaluate the safety and effectiveness of the Cerebral Protection System (model CEP016F, Shanghai Shenqi Medical Technology Co., Ltd.) for capturing and removing thrombotic and tissue debris during transcatheter aortic valve replacement (TAVR).
The target study population includes adult patients who are suitable for TAVR using commercially available domestic transcatheter aortic valve systems and whose vascular anatomy is appropriate for placement of the device in the brachiocephalic artery and left common carotid artery.
The planned sample size is 260 subjects.
Eligible subjects will be randomized in a 1:1 ratio to the device group (TAVR with the cerebral protection system) or the control group (TAVR without the device) using a centralized stratified randomization system based on valve type (self-expanding or balloon-expandable).
All subjects are planned to undergo follow-up within 24 hours after procedure, at 2±1 days, at 48-72 hours or before discharge (whichever comes first), and at 30 days after TAVR.
Studietype
Intervensjonell
Registrering (Faktiske)
260
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Xiamen, Kina
- Xiamen Cardiovascular Hospital Xiamen University
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Beskrivelse
Inclusion Criteria:
- Age ≥18 years, male or non-pregnant/non-lactating female.
- Suitable for TAVR and planned to undergo TAVR using an approved transcatheter aortic valve system.
- TAVR access limited to transfemoral or transapical approach.
- Imaging-confirmed left common carotid artery diameter of 6.5-10 mm and brachiocephalic artery diameter of 9-15 mm at the site of filter placement.
- No severe stenosis (>70%), dilation, dissection, ostial aneurysm, or aneurysm within 3 cm of the aortic origin in the target vessels.
- Brain imaging evaluable by 3-Tesla magnetic resonance imaging.
- Willing to comply with protocol-required follow-up assessments.
- Written informed consent provided by the subject or legal guardian.
Exclusion Criteria:
- Impaired right upper limb blood flow.
- Intracranial hemorrhage, stroke, or transient ischemic attack within 6 months before procedure.
- Acute myocardial infarction within 1 month before procedure.
- Calcification in the intended filter deployment region.
- Planned pacemaker or defibrillator implantation within 30 days after TAVR.
- Left ventricular ejection fraction ≤20%.
- Infective endocarditis, intracardiac/aortic mass, thrombus, or vegetation on echocardiography.
- Severe occlusive carotid disease requiring concomitant carotid intervention, or carotid stenting/endarterectomy within 6 weeks.
- Leukopenia, acute anemia, thrombocytopenia, bleeding diathesis, or coagulation disorder.
- Active peptic ulcer disease or gastrointestinal bleeding within 3 months.
- Severe allergy or known contraindication to nitinol, stainless steel alloy, or contrast media.
- Contraindication to antiplatelet and/or anticoagulation therapy, or refusal of blood transfusion.
- Severe renal insufficiency (serum creatinine >3.0 mg/dL, eGFR <30 mL/min, or need for renal replacement therapy).
- Known psychiatric disease or substance abuse that may interfere with compliance or data interpretation.
- Life expectancy <1 year.
- Active infection requiring concurrent antibiotic therapy.
- Other clinical conditions preventing compliance with the instructions for use of the investigational device.
- Concurrent use or planned use of another investigational device or drug during the study period.
- Severe tortuosity of right upper extremity vessels or inability to accommodate a 6 F sheath.
- Contraindication to MRI, including implanted pacemaker/defibrillator, metal implants, metal fragments, clips, or intracranial/ocular implanted devices.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Use of a cerebral embolic protection device during TAVR
|
The cerebral embolic protection device is a percutaneously delivered dual-filter protection device designed to capture and remove dislodged debris during transcatheter aortic valve replacement (TAVR).
The system utilizes one filter delivered to the brachiocephalic trunk (proximal filter) and a second filter delivered to the left common carotid artery (distal filter).
Upon completion of the procedure, the filters and debris are retrieved back into the catheter and removed from the patient.
|
|
Ingen inngripen: TAVR without the use of a cerebral embolic protection device
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The median total volume of new lesions within the protected brain territories, as assessed by diffusion-weighted magnetic resonance imaging (DW-MRI) at 2±1 days after TAVR.
Tidsramme: At 2±1 days after TAVR.
|
Protected brain territories are defined as the cerebral regions perfused exclusively by the vessels protected by the cerebral embolic protection device, namely the brachiocephalic artery and the left common carotid artery.
Total volume of new lesions is defined as the sum of all newly detected diffusion-positive brain lesions on post-TAVR DW-MRI relative to pre-TAVR DW-MRI.
|
At 2±1 days after TAVR.
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
20. september 2023
Primær fullføring (Faktiske)
16. april 2025
Studiet fullført (Faktiske)
16. april 2025
Datoer for studieregistrering
Først innsendt
22. mai 2026
Først innsendt som oppfylte QC-kriteriene
2. juni 2026
Først lagt ut (Faktiske)
4. juni 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
4. juni 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
2. juni 2026
Sist bekreftet
1. juni 2026
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- CEPD01-001
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .